Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC
Numerically higher biochemical response treatment difference was observed in the U.S. subgroup relative to the non-U.S. subgroup (∆ 60.7% vs. ∆ 41.6%) in patients with primary biliary cholangitis (PBC) Findings build on the clinical profile of saroglitazar in patients with PBC who have...
Covered in this story
Call it yourself
No calls on $POST yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Post Holdings →Dalsna Finance is currently tracking 8 stories mentioning Post Holdings, the earliest published 3 Mar 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.